Drug development is an arduous and expensive exercise. We seek to produce innovative compounds efficiently and effectively.

Analyst Coverage

Analyst	Firm
Rachel McMinn, Ph.D.	Banc of America Securities Merrill Lynch
Jason Zhang, Ph.D.	BMO Securities
Adam Cutler	Canaccord Adams
Yaron Werber, M.D.	Citigroup
Phil Nadeau	Cowen & Co.
Mark Schoenebaum	ISI Group
Liisa Bayko	JMP Securities
Geoffrey Meacham, Ph.D.	J.P. Morgan Securities
Terence Flynn	Lazard Capital Markets
Howard Liang, Ph.D.	Leerink Swann and Company
Subita Srimal	Mehta Partners
Alan Carr, Ph.D.	Needham & Company
Brian Abrahams, M.D.	Oppenheimer & Co. Inc.
Edward Tenthoff	Piper Jaffray
Jason Kantor, Ph.D.	RBC Capital
Thomas Russo	Robert W. Baird
Geoffrey Porges	Sanford Bernstein LLC
Carol Werther	Summer Street Research
Brian Skorney	ThinkEquity
Y. Katherine Xu, Ph.D.	Wedbush
John Sonnier	William Blair

Vertex Pharmaceuticals Incorporated is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Vertex Pharmaceuticals Incorporated's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vertex Pharmaceuticals Incorporated or its management. Vertex Pharmaceuticals Incorporated does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.